Chrysalis Therapeutics

Chrysalis BioTherapeutics is a clinical-stage biotechnology company focused on developing regenerative therapies for tissue repair and nuclear countermeasures. The company's lead candidate, TP508 (Chrysalin), is a synthetic 23-amino acid peptide derived from human thrombin that stimulates natural repair processes without inducing blood clotting. Chrysalis is advancing TP508 for indications including acute radiation syndrome (ARS), diabetic foot ulcers, and vascular complications associated with COVID-19. By targeting specific cell surface receptors, the technology aims to mitigate inflammation and promote revascularization in damaged tissues. The company leverages significant non-dilutive funding from federal agencies like BARDA and the NIH to support its development programs.